Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in ;proliferating hemangioma treated with propranolol
- VernacularTitle:普萘洛尔治疗增殖期血管瘤患者血管内皮生长因子-A及表皮生长因子样结构域7的表达分析
- Author:
Bin LING
1
,
2
;
Manli CHEN
;
Jie LIU
;
Xiaopeng YIN
;
Zhaoquan LIN
;
Zhongcheng GONG
Author Information
- Keywords: propranolol; proliferating infantile haemangioma; vascular endothelial growth factor-A; epidermal growth factor-like domain 7
- From: West China Journal of Stomatology 2014;(5):441-445
- CountryChina
- Language:Chinese
- Abstract: Objective This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment. Methods Propranolol (0.5-2 mg·kg-1) was orally administered to 30 infants every day for 4-8 months. The Achauer method was used to measure the tumor radius and thus evaluate the clinical curative effects of the treatment. Enzyme-linked immunosorbent assay was used to measure the serum and urinary concentrations of VEGF-A and EGFL7 at 0, 4, and 12 weeks after the treatment. Results The treatment response was excellent in 2 patients, good in 11, moderate in 14, and poor in 3. Serum VEGF-A (335.692 pg·mL-1±136.146 pg·mL-1) was high before the treatment and then significantly decreased after 4 weeks (264.853 pg·mL-1± 122.120 pg·mL-1) and 12 weeks (211.345 pg·mL-1± 104.035 pg·mL-1) of treatment (P<0.05). Urinary VEGF-A (76.234 pg·mL-1±24.169 pg·mL-1) was high before the treatment and then significantly decreased after four weeks (56.454 pg·mL-1±16.111 pg·mL-1) and twelve weeks (34.728 pg·mL-1±12.656 pg·mL-1) of treatment (P<0.05). Serum and urinary EGFL7 also decreased after the treatment, showing a positive relationship with VEGF-A. Conclusion Propranolol can be safely and effectively used to treat prolife-rating infantile hemangiomas. This treatment can reduce the peripheral serum and urinary concentrations of VEGF-A and EGFL7 in affected children.
